New York Hosp - Cornell Med Ctr
New York, 10021, United States
NCT Number: NCT00002433
To determine safety and tolerance of administering aerosolized recombinant interferon gamma (IFN-gamma) for 4 weeks in patients with AIDS. To examine activation of alveolar macrophages by aerosolized IFN-gamma administration. To determine if subcutaneous (SC) injection of IFN-gamma can activate alveolar macrophages in AIDS patients.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
New York, 10021, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Patients must have:
Exclusion criteria
Co-existing Condition:
Patients with the following conditions or symptoms are excluded:
Patients with the following are excluded:
Prior Medication:
Excluded within 4 weeks of study entry:
Looking for future studies?
Notify MeAmgen
Industry
Activation of Alveolar Macrophages by Aerosolized r-metHuIFN-Gamma (IFN-Gamma) in Patients With AIDS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04766710
AIDS, Acquired Immunodeficiency Syndrome
Phnom Penh, Cambodia
View Trial DetailsNCT01645865
AIDS, Acquired Immunodeficiency Syndrome
Nairobi, Kenya
View Trial DetailsNCT05510908
AIDS Related Lymphoma, AIDS-Related Kaposi Sarcoma
La Jolla, California, United States
View Trial DetailsNCT07750834
Acquired Immunodeficiency Syndrome, Behavior
Khartoum, Omdurman, Sudan
View Trial Details